10x Genomics today announced a multi-year research initiative with Dana-Farber Cancer Institute to apply its Chromium Flex single cell assay and Xenium spatial platform to analyze tumor biopsies from several hundred patients with major solid tumor types. The study will evaluate emerging oncology modalities—antibody-drug conjugates, radioligand therapies, bispecific antibodies and checkpoint inhibitors—by mapping cellular composition, immune contexture and spatial architecture and correlating these molecular profiles with documented clinical outcomes such as progression-free survival and objective response rates. The goal is to identify actionable biomarkers linked to treatment response and resistance, and to define a standardized clinical reporting framework that can be integrated into precision oncology workflows.

In parallel, 10x Genomics will establish a CLIA-certified laboratory in Pleasanton, California, with planned completion in Q4 2026. The facility will house dedicated instrumentation for sample processing, assay implementation and analytical validation under regulated conditions. Initial capacity targets are 10,000 clinical samples per year, scaling to 50,000 by 2028. This infrastructure will support assay performance benchmarks—sensitivity, specificity and reproducibility metrics meeting FDA guidelines—and enable internal validation studies required for future diagnostic test submissions.

This collaboration and CLIA build-out position 10x Genomics to enter the molecular diagnostics market, estimated at $15 billion annually for oncology testing in the U.S. alone. By converting flagship research platforms into clinically validated assays, management targets a diagnostic services revenue stream beginning in 2027, supplementing existing instrument and consumables sales. Successful identification of robust biomarkers and publication of peer-reviewed clinical data could accelerate adoption by academic and commercial labs, supporting long-term revenue growth and expanding the company’s TAM in precision oncology diagnostics.